TDMS Study 05058-02 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Southern Research Inst ROXARSONE DATE: 09/08/94
EXPERIMENT: 05058 TEST: 02 TIME: 14:26:00
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: NOI-ES-28024 ROUTE: DOSED FEED NTP C#: C56508
PATHOLOGIST: D. FARNELL CAS: 121-19-7
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Southern Research Inst ROXARSONE DATE: 09/08/94
EXPERIMENT: 05058 TEST: 02 TIME: 14:26:00
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NOI-ES-28024 ROUTE: DOSED FEED NTP C#: C56508
PATHOLOGIST: D. FARNELL CAS: 121-19-7
MICE(B6C3F1)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Bone Marrow
Brain
Clitoral Gland
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Southern Research Inst ROXARSONE DATE: 09/08/94
EXPERIMENT: 05058 TEST: 02 TIME: 14:26:00
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NOI-ES-28024 ROUTE: DOSED FEED NTP C#: C56508
PATHOLOGIST: D. FARNELL CAS: 121-19-7
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF ROXARSONE
====================================================================================================
MALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Adrenal Cortex Adenoma
Adrenal Medulla Pheochromocytoma Benign
Liver Hepatocellular Adenoma
Lung Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
All Organs Hemangiosarcoma
Hemangiosarcoma or Hemangioma
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Liver Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
All Organs Malignant Lymphoma And Histiocytic Sarcoma
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed,
NOS, or Undifferentiated Cell Type
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 4/49 (8%) | 0/50 (0%) 0/49 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 5.0% 12.1% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 2/40 (5%) 4/33 (12%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | --- 729 (T) 729 (T) | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.044 * P=0.328 P=0.090 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.044 * P=0.328 P=0.090 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.044 * P=0.328 P=0.090 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.035 * | (e) |
|FISHER EXACT | P=0.247 P=0.056 | (e) (e) |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 0/50 (0%) 0/49 (0%) | 0/50 (0%) 0/49 (0%) 0/50 (0%) |
|ADJUSTED (b) | 9.1% 0.0% 0.0% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/40 (0%) 0/33 (0%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 618 --- --- | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.028N* P=0.082N P=0.106N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.049N* P=0.174N P=0.132N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.038N* P=0.117N P=0.121N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.038N* | (e) |
|FISHER EXACT | P=0.121N P=0.125N | (e) (e) |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma: Benign, Complex, Malignant, NOS |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 0/50 (0%) 1/49 (2%) | 0/50 (0%) 0/49 (0%) 0/50 (0%) |
|ADJUSTED (b) | 9.1% 0.0% 2.3% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/40 (0%) 0/33 (0%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 618 --- 641 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.153N P=0.082N P=0.275N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.196N P=0.174N P=0.316N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.182N P=0.117N P=0.312N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.180N | (e) |
|FISHER EXACT | P=0.121N P=0.316N | (e) (e) |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 3/50 (6%) | 1/50 (2%) 2/50 (4%) 1/50 (2%) |
|ADJUSTED (b) | 2.9% 5.0% 8.4% | 7.1% 8.0% 3.4% |
|TERMINAL (d) | 0/27 (0%) 2/40 (5%) 2/33 (6%) | 1/14 (7%) 1/18 (6%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 668 729 (T) 659 | 729 (T) 530 601 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.262 P=0.616 P=0.361 | P=0.604N P=0.558 P=0.754N |
|INCIDENTAL TUMOR | P=0.214 P=0.521 P=0.275 | P=0.537N P=0.584 P=0.669N |
|LOGISTIC REGRESSION | P=0.228 P=0.535 P=0.312 | P=0.621N P=0.506 P=0.761 |
|COCHRAN-ARMITAGE | P=0.222 | P=0.622N |
|FISHER EXACT | P=0.500 P=0.309 | P=0.500 P=0.753N |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 9/50 (18%) 8/50 (16%) 3/50 (6%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 27.0% 18.3% 8.3% | 3.6% 0.0% 0.0% |
|TERMINAL (d) | 5/27 (19%) 5/40 (13%) 2/33 (6%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 618 645 653 | 658 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.029N* P=0.247N P=0.039N* | P=0.295N P=0.539N P=0.531N |
|INCIDENTAL TUMOR | P=0.058N P=0.521N P=0.063N | P=0.387N P=0.625N P=0.652N |
|LOGISTIC REGRESSION | P=0.046N* P=0.435N P=0.055N | P=0.269N P=0.497N P=0.500N |
|COCHRAN-ARMITAGE | P=0.053N | P=0.269N |
|FISHER EXACT | P=0.500N P=0.061N | P=0.500N P=0.500N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 8/50 (16%) 5/50 (10%) | 2/50 (4%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 10.9% 17.6% 12.3% | 6.8% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 4/40 (10%) 1/33 (3%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 623 560 641 | 635 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.519 P=0.339 P=0.565 | P=0.122N P=0.279N P=0.286N |
|INCIDENTAL TUMOR | P=0.336 P=0.056 P=0.355 | P=0.104N P=0.275N P=0.241N |
|LOGISTIC REGRESSION | P=0.357 P=0.161 P=0.437 | P=0.094N P=0.234N P=0.237N |
|COCHRAN-ARMITAGE | P=0.437 | P=0.095N |
|FISHER EXACT | P=0.178 P=0.500 | P=0.247N P=0.247N |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 12/50 (24%) 15/50 (30%) 7/50 (14%) | 3/50 (6%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 33.3% 32.3% 17.8% | 10.1% 0.0% 0.0% |
|TERMINAL (d) | 5/27 (19%) 9/40 (23%) 3/33 (9%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 618 560 641 | 635 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.086N P=0.496N P=0.105N | P=0.054N P=0.158N P=0.160N |
|INCIDENTAL TUMOR | P=0.168N P=0.210 P=0.188N | P=0.059N P=0.179N P=0.163N |
|LOGISTIC REGRESSION | P=0.154N P=0.211 P=0.142N | P=0.037N* P=0.117N P=0.120N |
|COCHRAN-ARMITAGE | P=0.141N | P=0.037N* |
|FISHER EXACT | P=0.326 P=0.154N | P=0.121N P=0.121N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 12/50 (24%) 15/50 (30%) 7/50 (14%) | 3/50 (6%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 33.3% 32.3% 17.8% | 10.1% 0.0% 0.0% |
|TERMINAL (d) | 5/27 (19%) 9/40 (23%) 3/33 (9%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 618 560 641 | 635 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.086N P=0.496N P=0.105N | P=0.054N P=0.158N P=0.160N |
|INCIDENTAL TUMOR | P=0.168N P=0.210 P=0.188N | P=0.059N P=0.179N P=0.163N |
|LOGISTIC REGRESSION | P=0.154N P=0.211 P=0.142N | P=0.037N* P=0.117N P=0.120N |
|COCHRAN-ARMITAGE | P=0.141N | P=0.037N* |
|FISHER EXACT | P=0.326 P=0.154N | P=0.121N P=0.121N |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 3/50 (6%) 9/50 (18%) | 1/50 (2%) 3/50 (6%) 3/50 (6%) |
|ADJUSTED (b) | 16.4% 7.2% 25.5% | 4.3% 16.7% 16.7% |
|TERMINAL (d) | 3/27 (11%) 2/40 (5%) 7/33 (21%) | 0/14 (0%) 3/18 (17%) 2/17 (12%) |
|FIRST INCIDENCE (DAYS) | 665 678 702 | 684 729 (T) 718 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.197 P=0.196N P=0.304 | P=0.288 P=0.360 P=0.356 |
|INCIDENTAL TUMOR | P=0.131 P=0.343N P=0.213 | P=0.199 P=0.314 P=0.208 |
|LOGISTIC REGRESSION | P=0.157 P=0.285N P=0.246 | P=0.241 P=0.303 P=0.298 |
|COCHRAN-ARMITAGE | P=0.135 | P=0.238 |
|FISHER EXACT | P=0.357N P=0.194 | P=0.309 P=0.309 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 2/50 (4%) 1/50 (2%) | 2/50 (4%) 1/50 (2%) 2/50 (4%) |
|ADJUSTED (b) | 20.8% 5.0% 3.0% | 12.0% 2.4% 7.6% |
|TERMINAL (d) | 5/27 (19%) 2/40 (5%) 1/33 (3%) | 1/14 (7%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 668 729 (T) 729 (T) | 710 521 606 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.013N* P=0.047N* P=0.033N* | P=0.605 P=0.477N P=0.689 |
|INCIDENTAL TUMOR | P=0.017N* P=0.063N P=0.040N* | P=0.558 P=0.516N P=0.639 |
|LOGISTIC REGRESSION | P=0.018N* P=0.074N P=0.043N* | P=0.608N P=0.494N P=0.690 |
|COCHRAN-ARMITAGE | P=0.029N* | P=0.610 |
|FISHER EXACT | P=0.134N P=0.056N | P=0.500N P=0.691N |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 5/50 (10%) 10/50 (20%) | 3/50 (6%) 4/50 (8%) 5/50 (10%) |
|ADJUSTED (b) | 35.7% 12.0% 28.4% | 15.9% 18.7% 23.0% |
|TERMINAL (d) | 8/27 (30%) 4/40 (10%) 8/33 (24%) | 1/14 (7%) 3/18 (17%) 2/17 (12%) |
|FIRST INCIDENCE (DAYS) | 665 678 702 | 684 521 606 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.302N P=0.017N* P=0.326N | P=0.335 P=0.563 P=0.394 |
|INCIDENTAL TUMOR | P=0.405N P=0.043N* P=0.431N | P=0.229 P=0.500 P=0.235 |
|LOGISTIC REGRESSION | P=0.372N P=0.039N* P=0.400N | P=0.272 P=0.499 P=0.336 |
|COCHRAN-ARMITAGE | P=0.447N | P=0.290 |
|FISHER EXACT | P=0.086N P=0.500N | P=0.500 P=0.357 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 2/50 (4%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 12.9% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/40 (0%) 0/33 (0%) | 1/14 (7%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 716 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.079N P=0.200N P=0.206N |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.127N P=0.275N P=0.295N |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.088N P=0.225N P=0.222N |
|COCHRAN-ARMITAGE | (e) | P=0.095N |
|FISHER EXACT | (e) (e) | P=0.247N P=0.247N |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/45 (0%) 0/46 (0%) 0/45 (0%) | 6/49 (12%) 3/46 (7%) 4/49 (8%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 32.1% 16.7% 19.4% |
|TERMINAL (d) | 0/24 (0%) 0/38 (0%) 0/30 (0%) | 3/14 (21%) 3/18 (17%) 3/17 (18%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 676 729 (T) 483 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.224N P=0.177N P=0.295N |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.318N P=0.270N P=0.421N |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.315N P=0.239N P=0.392N |
|COCHRAN-ARMITAGE | (e) | P=0.298N |
|FISHER EXACT | (e) (e) | P=0.276N P=0.370N |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Intermedia |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/45 (0%) 0/46 (0%) 0/45 (0%) | 0/49 (0%) 0/46 (0%) 2/49 (4%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 0.0% 0.0% 10.2% |
|TERMINAL (d) | 0/24 (0%) 0/38 (0%) 0/30 (0%) | 0/14 (0%) 0/18 (0%) 1/17 (6%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | --- --- 679 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.103 (e) P=0.256 |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.067 (e) P=0.176 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.092 (e) P=0.228 |
|COCHRAN-ARMITAGE | (e) | P=0.098 |
|FISHER EXACT | (e) (e) | (e) P=0.247 |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 4/50 (8%) 4/50 (8%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 14.0% 10.0% 11.8% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 3/27 (11%) 4/40 (10%) 3/33 (9%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 714 729 (T) 711 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.477N P=0.426N P=0.547N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.527N P=0.491N P=0.611N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.506N P=0.467N P=0.577N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.573 | (e) |
|FISHER EXACT | P=0.643N P=0.643N | (e) (e) |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Fibrosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 3/50 (6%) 7/50 (14%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 15.8% 7.3% 16.7% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 2/40 (5%) 2/33 (6%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 618 712 603 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.507 P=0.143N P=0.574 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.364 P=0.397N P=0.419 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.363 P=0.247N P=0.394 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.436 | (e) |
|FISHER EXACT | P=0.243N P=0.500 | (e) (e) |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Neurofibrosarcoma, Fibrosarcoma, Sarcoma, |
| Neurofibroma, or Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 14/50 (28%) 13/50 (26%) 16/50 (32%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 36.1% 28.8% 35.9% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 4/27 (15%) 8/40 (20%) 6/33 (18%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 618 645 432 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.515 P=0.209N P=0.559 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.226 P=0.473 P=0.263 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.255 P=0.460 P=0.259 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.370 | (e) |
|FISHER EXACT | P=0.500N P=0.414 | (e) (e) |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Neurofibrosarcoma, Fibrosarcoma, or Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 9/50 (18%) 13/50 (26%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 27.7% 19.9% 29.1% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 4/40 (10%) 4/33 (12%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 618 645 432 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.466 P=0.204N P=0.520 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.168 P=0.424 P=0.207 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.199 P=0.436 P=0.202 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.359 | (e) |
|FISHER EXACT | P=0.402N P=0.408 | (e) (e) |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 6/50 (12%) 6/50 (12%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 14.1% 13.4% 14.6% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 2/40 (5%) 2/33 (6%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 653 645 432 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.508 P=0.563N P=0.569 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.263 P=0.185 P=0.341 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.436 P=0.196 P=0.498 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.437 | (e) |
|FISHER EXACT | P=0.500 P=0.500 | (e) (e) |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Schwannoma NOS |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 1/50 (2%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 6.7% 0.0% 2.1% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/40 (0%) 0/33 (0%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 710 --- 480 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.331N P=0.168N P=0.464N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.476N P=0.257N P=0.597N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.360N P=0.194N P=0.500N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.360N | (e) |
|FISHER EXACT | P=0.247N P=0.500N | (e) (e) |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Spleen |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 0/50 (0%) 0/49 (0%) |
|ADJUSTED (b) | 7.4% 0.0% 0.0% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/27 (7%) 0/40 (0%) 0/33 (0%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) --- --- | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.068N P=0.157N P=0.195N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.068N P=0.157N P=0.195N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.068N P=0.157N P=0.195N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.095N | (e) |
|FISHER EXACT | P=0.247N P=0.247N | (e) (e) |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/48 (4%) 2/50 (4%) | 0/49 (0%) 0/49 (0%) 0/49 (0%) |
|ADJUSTED (b) | 0.0% 5.3% 6.1% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 2/38 (5%) 2/33 (6%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | --- 729 (T) 729 (T) | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.207 P=0.316 P=0.283 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.207 P=0.316 P=0.283 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.207 P=0.316 P=0.283 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.177 | (e) |
|FISHER EXACT | P=0.237 P=0.247 | (e) (e) |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/48 (4%) 3/50 (6%) | 0/49 (0%) 0/49 (0%) 0/49 (0%) |
|ADJUSTED (b) | 0.0% 5.3% 9.1% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 2/38 (5%) 3/33 (9%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | --- 729 (T) 729 (T) | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.099 P=0.316 P=0.158 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.099 P=0.316 P=0.158 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.099 P=0.316 P=0.158 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.083 | (e) |
|FISHER EXACT | P=0.237 P=0.121 | (e) (e) |
|=================================================================================================================================|
| |
|All Organs |
| Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 0/50 (0%) | 0/50 (0%) 2/50 (4%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 2.5% 0.0% | 0.0% 9.8% 0.0% |
|TERMINAL (d) | 0/27 (0%) 1/40 (3%) 0/33 (0%) | 0/14 (0%) 1/18 (6%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | --- 729 (T) --- | --- 662 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.716N P=0.578 (e) | P=0.666N P=0.243 (e) |
|INCIDENTAL TUMOR | P=0.716N P=0.578 (e) | P=0.602 P=0.196 (e) |
|LOGISTIC REGRESSION | P=0.716N P=0.578 (e) | P=0.663 P=0.235 (e) |
|COCHRAN-ARMITAGE | P=0.731 | P=0.669 |
|FISHER EXACT | P=0.500 (e) | P=0.247 (e) |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 0/50 (0%) 1/50 (2%) |
|ADJUSTED (b) | 9.4% 0.0% 0.0% | 0.0% 0.0% 3.1% |
|TERMINAL (d) | 2/27 (7%) 0/40 (0%) 0/33 (0%) | 0/14 (0%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 535 --- --- | --- --- 591 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.026N* P=0.077N P=0.100N | P=0.261 (e) P=0.488 |
|INCIDENTAL TUMOR | P=0.056N P=0.157N P=0.134N | P=0.358 (e) P=0.623 |
|LOGISTIC REGRESSION | P=0.038N* P=0.129N P=0.121N | P=0.261 (e) P=0.492 |
|COCHRAN-ARMITAGE | P=0.037N* | P=0.269 |
|FISHER EXACT | P=0.121N P=0.121N | (e) P=0.500 |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 1/50 (2%) 0/50 (0%) | 0/50 (0%) 2/50 (4%) 1/50 (2%) |
|ADJUSTED (b) | 9.4% 2.5% 0.0% | 0.0% 9.8% 3.1% |
|TERMINAL (d) | 2/27 (7%) 1/40 (3%) 0/33 (0%) | 0/14 (0%) 1/18 (6%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 535 729 (T) --- | --- 662 591 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.042N* P=0.204N P=0.100N | P=0.357 P=0.243 P=0.488 |
|INCIDENTAL TUMOR | P=0.074N P=0.364N P=0.134N | P=0.360 P=0.196 P=0.623 |
|LOGISTIC REGRESSION | P=0.061N P=0.310N P=0.121N | P=0.359 P=0.235 P=0.492 |
|COCHRAN-ARMITAGE | P=0.060N | P=0.360 |
|FISHER EXACT | P=0.309N P=0.121N | P=0.247 P=0.500 |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 1/50 (2%) 3/50 (6%) | 13/50 (26%) 2/50 (4%) 3/50 (6%) |
|ADJUSTED (b) | 15.6% 2.5% 8.3% | 52.0% 9.3% 9.6% |
|TERMINAL (d) | 3/27 (11%) 1/40 (3%) 1/33 (3%) | 5/14 (36%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 647 729 (T) 702 | 170 662 534 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.205N P=0.050N P=0.285N | P=0.003N** P=0.003N** P=0.010N* |
|INCIDENTAL TUMOR | P=0.297N P=0.086N P=0.400N | P=0.010N** P=0.010N** P=0.021N* |
|LOGISTIC REGRESSION | P=0.249N P=0.086N P=0.336N | P=0.002N** P=0.002N** P=0.007N** |
|COCHRAN-ARMITAGE | P=0.264N | P=0.002N** |
|FISHER EXACT | P=0.102N P=0.357N | P=0.002N** P=0.006N** |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 1/50 (2%) 3/50 (6%) | 13/50 (26%) 2/50 (4%) 3/50 (6%) |
|ADJUSTED (b) | 15.6% 2.5% 8.3% | 52.0% 9.3% 9.6% |
|TERMINAL (d) | 3/27 (11%) 1/40 (3%) 1/33 (3%) | 5/14 (36%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 647 729 (T) 702 | 170 662 534 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.205N P=0.050N P=0.285N | P=0.003N** P=0.003N** P=0.010N* |
|INCIDENTAL TUMOR | P=0.297N P=0.086N P=0.400N | P=0.010N** P=0.010N** P=0.021N* |
|LOGISTIC REGRESSION | P=0.249N P=0.086N P=0.336N | P=0.002N** P=0.002N** P=0.007N** |
|COCHRAN-ARMITAGE | P=0.264N | P=0.002N** |
|FISHER EXACT | P=0.102N P=0.357N | P=0.002N** P=0.006N** |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 18/50 (36%) 20/50 (40%) 20/50 (40%) | 11/50 (22%) 9/50 (18%) 13/50 (26%) |
|ADJUSTED (b) | 50.4% 46.3% 52.4% | 46.3% 40.1% 56.7% |
|TERMINAL (d) | 10/27 (37%) 17/40 (43%) 15/33 (45%) | 3/14 (21%) 6/18 (33%) 8/17 (47%) |
|FIRST INCIDENCE (DAYS) | 618 645 653 | 635 530 483 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.465N P=0.249N P=0.497N | P=0.429 P=0.344N P=0.485 |
|INCIDENTAL TUMOR | P=0.410 P=0.578 P=0.441 | P=0.282 P=0.495N P=0.283 |
|LOGISTIC REGRESSION | P=0.473 P=0.528N P=0.522 | P=0.313 P=0.404N P=0.358 |
|COCHRAN-ARMITAGE | P=0.379 | P=0.359 |
|FISHER EXACT | P=0.418 P=0.418 | P=0.402N P=0.408 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 26/50 (52%) 18/50 (36%) 21/50 (42%) | 18/50 (36%) 3/50 (6%) 5/50 (10%) |
|ADJUSTED (b) | 58.6% 36.7% 45.2% | 64.8% 11.5% 14.7% |
|TERMINAL (d) | 9/27 (33%) 9/40 (23%) 8/33 (24%) | 6/14 (43%) 0/18 (0%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 456 560 432 | 170 521 485 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.122N P=0.018N* P=0.144N | P=0.001N** P<0.001N** P=0.005N** |
|INCIDENTAL TUMOR | P=0.367N P=0.384N P=0.397N | P=0.003N** P=0.001N** P=0.007N** |
|LOGISTIC REGRESSION | P=0.345N P=0.262N P=0.369N | P<0.001N** P<0.001N** P=0.002N** |
|COCHRAN-ARMITAGE | P=0.182N | P<0.001N** |
|FISHER EXACT | P=0.079N P=0.212N | P<0.001N** P=0.002N** |
|=================================================================================================================================|
DATE: 09/08/94 EXPERIMENT: 05058 TEST: 02 PAGE 16
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ROXARSONE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | UNTREATD 0.01% 0.02% | UNTREATD 0.01% 0.02% |
| | CONTROL | CONTROL |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 35/50 (70%) 30/50 (60%) 34/50 (68%) | 24/50 (48%) 11/50 (22%) 18/50 (36%) |
|ADJUSTED (b) | 77.7% 61.2% 70.8% | 80.8% 44.5% 63.1% |
|TERMINAL (d) | 17/27 (63%) 21/40 (53%) 19/33 (58%) | 9/14 (64%) 6/18 (33%) 8/17 (47%) |
|FIRST INCIDENCE (DAYS) | 456 560 432 | 170 521 483 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.221N P=0.016N* P=0.239N | P=0.118N P=0.006N** P=0.153N |
|INCIDENTAL TUMOR | P=0.460 P=0.339N P=0.526 | P=0.233N P=0.013N* P=0.287N |
|LOGISTIC REGRESSION | P=0.481 P=0.257N P=0.561 | P=0.121N P=0.005N** P=0.148N |
|COCHRAN-ARMITAGE | P=0.458N | P=0.125N |
|FISHER EXACT | P=0.201N P=0.500N | P=0.006N** P=0.156N |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).
--multipart-boundary
Content-type: text/plain
Range: bytes 112962-112962/112962
--multipart-boundary--